中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 36 Issue 6
Jun.  2020
Turn off MathJax
Article Contents

Advances in immune checkpoint inhibitor combined with other treatment methods for hepatocellular carcinoma

DOI: 10.3969/j.issn.1001-5256.2020.06.043
Research funding:

 

  • Published Date: 2020-06-20
  • In recent years,immune checkpoint inhibitor( ICI) in the treatment of unresectable liver cancer has attracted great attention in China and foreign countries and great progress has been achieved,but ICI monotherapy cannot bring benefits to most patients with liver cancer. Therefore,it is a new trend to explore the combination of ICI with other treatment methods. This article summarizes the advances in ICI combination therapy for unresectable liver cancer in China and foreign countries,including ICI combined with molecular targeted therapy,PD-1/PD-L1 inhibitor combined with CTLA-4 inhibitor,and ICI combined with local therapy. The results show that for patients with unresectable liver cancer,ICI combined with other treatment methods has a significantly better effect than ICI monotherapy; however,further studies are needed to explore which treatment method combined with ICI can bring the greatest benefits to patients.

     

  • loading
  • [1] BRAY F,FERLAY J,SOERJOMATARAM I,et al. Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin,2018,68(6):394-424.
    [2] BOLAND P,WU J. Systemic therapy for hepatocellular carcinoma:Beyond sorafenib[J]. Chin Clin Oncol,2018,7(5):50.
    [3] LIN CL,CHIEN RN,LIN SM,et al. An occult hepatitis B-derived hepatoma cell line carrying persistent nuclear viral DNA and permissive for exogenous hepatitis B virus infection[J].PLo S One,2013,8(5):e65456.
    [4] KNOLLE PA,THIMME R. Hepatic immune regulation and its involvement in viral hepatitis infection[J]. Gastroenterology,2014,146(5):1193-1207.
    [5] IWAI Y,HAMANISHI J,CHAMOTO K,et al. Cancer immunotherapies targeting the PD-1 signaling pathway[J]. J Biomed Sci,2017,24(1):26.
    [6] SIA D,JIAO Y,MARTINEZ-QUETGLAS I,et al. Identification of an immune-specific class of hepatocellular carcinoma,based on molecular features[J]. Gastroenterology,2017,153(3):812-826.
    [7] LIU Z,LIN Y,ZHANG J,et al. Molecular targeted and immune checkpoint therapy for advanced hepatocellular carcinoma[J]. J Exp Clin Cancer Res,2019,38(1):447.
    [8] LIANG SC,LATCHMAN YE,BUHLMANN JE,et al. Regulation of PD-1,PD-L1,and PD-L2 expression during normal and autoimmune responses[J]. Eur J Immunol,2003,33(10):2706-2716.
    [9] CAO YQ,JIN X,SUI SN,et al. Advances of chimeric antigen receptor T-cell immunotherapy combined with immune checkpoint inhibitors in malignancies therapy[J]. Chin J Clin Oncol,2018,45(9):472-476.(in Chinese)曹雅青,金鑫,隋松男,等.嵌合抗原受体T细胞联合免疫检查点抑制剂治疗恶性肿瘤的研究进展[J].中国肿瘤临床,2018,45(9):472-476.
    [10] CUI YL. Targeted therapy for hepatocellular carcinoma[J].Chin J Dig Surg,2018,17(5):445-451.(in Chinese)崔云龙.肝癌的靶向治疗[J].中华消化外科杂志,2018,17(5):445-451.
    [11] XU W,LIU K,CHEN M,et al. Immunotherapy for hepatocellular carcinoma:Recent advances and future perspectives[J].Ther Adv Med Oncol,2019,11:1758835919862692.
    [12] HANAHAN D,WEINBERG RA. Hallmarks of cancer:The next generation[J]. Cell,2011,144(5):646-674.
    [13] SWART M,VERBRUGGE I,BELTMAN JB. Combination approaches with immune-checkpoint blockade in cancer therapy[J]. Front Oncol,2016,6:233.
    [14] LARKIN J,CHIARION-SILENI V,GONZALEZ R,et al. Combined Nivolumab and Ipilimumab or monotherapy in untreated melanoma[J]. N Engl J Med,2015,373(1):23-34.
    [15] KELLEY RK,ABOU-ALFA GK,BENDELL JC,et al. PhaseⅠ/Ⅱstudy of durvalumab and tremelimumab in patients with unresectable hepatocellular carcinoma(HCC):PhaseⅠsafety and efficacy analyses[J]. J Clin Oncol,2017,35(15 Suppl):4073.
    [16] YUAN GQ,MO CJ,ZHANG ZC. Clinical effect of TACE combined with radiofrequency ablation in the treatment of primary liver cancer[J]. Clin J Med Offic,2019,47(10):1126-1127.(in Chinese)袁广庆,莫灿均,张志成.肝动脉化疗栓塞联合射频消融治疗原发性肝癌临床疗效观察[J].临床军医杂志,2019,47(10):1126-1127.
    [17] GRETEN TF,SANGRO B. Targets for immunotherapy of liver cancer[J]. J Hepatol,2017.[Online ahead of print]
    [18] LEE S,KIM H,JI Y,et al. Evaluation of hepatic toxicity after repeated stereotactic body radiation therapy for recurrent hepatocellular carcinoma using deformable image registration[J].Sci Rep,2018,8(1):16224.
    [19] ABUODEH Y,VENKAT P,KIM S. Systematic review of case reports on the abscopal effect[J]. Curr Probl Cancer,2016,40(1):25-37.
    [20] LENCIONI R,de BAERE T,SOULEN MC,et al. Lipiodol transarterial chemoembolization for hepatocellular carcinoma:A systematic review of efficacy and safety data[J]. Hepatology,2016,64(1):106-116.
    [21] de TONI EN. Immune checkpoint inhibitors:Use them early,combined and instead of TACE?[J]. Gut,2019.[Online ahead of print]
    [22] EL-KHOUEIRY AB,SANGRO B,YAU T,et al. Nivolumab in patients with advanced hepatocellular carcinoma(CheckMate 040):An open-label,non-comparative,phase 1/2 dose escalation and expansion trial[J]. Lancet,2017,389(10088):2492-2502.
    [23] SHI L,CHEN L,WU C,et al. PD-1 blockade boosts radiofrequency ablation-elicited adaptive immune responses against tumor[J]. Clin Cancer Res,2016,22(5):1173-1184.
    [24] DUFFY AG,ULAHANNAN SV,MAKOROVA-RUSHER O,et al.Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma[J]. J Hepatol,2017,66(3):545-551.
    [25] SANGRO B,GOMEZ-MARTIN C,de la MATA M,et al. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C[J]. J Hepatol,2013,59(1):81-88.
    [26] Correction:Gut roundtable meeting paper:Selected recent advances in hepatocellular carcinoma[J]. Gut,2018,67(3):594.
    [27] MARTINS F,SOFIYA L,SYKIOTIS GP,et al. Adverse effects of immune-checkpoint inhibitors:Epidemiology,management and surveillance[J]. Nat Rev Clin Oncol,2019,16(9):563-580.
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Article Metrics

    Article views (782) PDF downloads(148) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return